ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

Projektinformationen

UNITE4TB

ID Finanzhilfevereinbarung: 101007873

DOI 10.3030/101007873

EK-Unterschriftsdatum 29 Juni 2021

Startdatum 1 Juni 2021

Enddatum 31 Mai 2028

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 185 000 000,00

EU-Beitrag € 92 500 000,00

Koordiniert durch

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

Leistungen

Documents, reports (6)

Report of kick-off meeting

Report of kickoff meeting

Communication and dissemination plan
Establish CAG
Establish SAB and RAB
Report of first annual consortium meeting
Establish EAB

Other (2)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group

Websites, patent fillings, videos etc. (1)

Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Veröffentlichungen

Peer reviewed articles (5)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Autoren: Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Veröffentlicht in: Pharmaceutics, 2022, ISSN 1999-4923
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

Tuberculosis: current challenges and beyond

Autoren: Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Veröffentlicht in: Breath, 2023, ISSN 2073-4735
Herausgeber: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Autoren: Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Veröffentlicht in: Clinical Microbiology Reviews, Ausgabe 21 March 2022, 2022, Seite(n) n/a, ISSN 1098-6618
Herausgeber: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Autoren: Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Veröffentlicht in: Breath, 2023, ISSN 2073-4735
Herausgeber: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Autoren: Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Veröffentlicht in: Front. Pharmacol., 2023, ISSN 1663-9812
Herausgeber: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

Non-peer reviewed articles (1)

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Autoren: Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Veröffentlicht in: International Union Against Tuberculosis and Lung Disease, Ausgabe Volume 25, Number 11, 1 November 2021, 2021, Seite(n) 886-889, ISSN 1027-3719
Herausgeber: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515